- Home
- FINS vs RGNX Comparison
FINS vs RGNX Comparison
Compare FINS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINS
- RGNX
- Stock Information
- Founded
- FINS 2019
- RGNX 2008
- Country
- FINS United States
- RGNX United States
- Employees
- FINS N/A
- RGNX N/A
- Industry
- FINS Finance/Investors Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FINS Finance
- RGNX Health Care
- Exchange
- FINS Nasdaq
- RGNX Nasdaq
- Market Cap
- FINS 442.1M
- RGNX 451.1M
- IPO Year
- FINS N/A
- RGNX 2015
- Fundamental
- Price
- FINS $13.27
- RGNX $9.71
- Analyst Decision
- FINS
- RGNX Strong Buy
- Analyst Count
- FINS 0
- RGNX 8
- Target Price
- FINS N/A
- RGNX $28.50
- AVG Volume (30 Days)
- FINS 78.0K
- RGNX 673.5K
- Earning Date
- FINS 01-01-0001
- RGNX 11-05-2025
- Dividend Yield
- FINS 9.97%
- RGNX N/A
- EPS Growth
- FINS N/A
- RGNX N/A
- EPS
- FINS N/A
- RGNX N/A
- Revenue
- FINS N/A
- RGNX $155,782,000.00
- Revenue This Year
- FINS N/A
- RGNX $260.25
- Revenue Next Year
- FINS N/A
- RGNX N/A
- P/E Ratio
- FINS N/A
- RGNX N/A
- Revenue Growth
- FINS N/A
- RGNX 74.95
- 52 Week Low
- FINS $11.61
- RGNX $5.04
- 52 Week High
- FINS $12.57
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- FINS 59.17
- RGNX 60.66
- Support Level
- FINS $13.13
- RGNX $8.68
- Resistance Level
- FINS $13.35
- RGNX $9.19
- Average True Range (ATR)
- FINS 0.10
- RGNX 0.50
- MACD
- FINS -0.00
- RGNX 0.12
- Stochastic Oscillator
- FINS 73.68
- RGNX 87.85
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.